Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Nycomed licenses TransMID from KS Biomedix in Europe

Sep. 20, 2002

Edrecolomab effective against bone marrow metastases of breast cancer

Sep. 17, 2002

INDs filed for M-Vax and O-Vax

Sep. 16, 2002

Melacine rights return to Corixa

Sep. 13, 2002

Zadaxin enters phase II combination trial in malignant melanoma

Sep. 12, 2002

PI-88 enters phase I in combination with Taxotere

Sep. 10, 2002

Kirin initiates phase II Mylovenge trials in Japan

Sep. 9, 2002

Enrollment completed in phase II study of EGF cancer vaccine

Sep. 6, 2002

Pfizer and Abgenix disclose monoclonal antibodies that specifically bind to IGF-IR

Sep. 3, 2002

Novuspharma and Micromet to codevelop MT-201 for cancer

Sep. 3, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Sumitomo’s DSP-3456 exerts antidepressant-like effects
BioWorld Science
About one-third of patients with major depressive disorder (MDD) are treatment resistant. Ketamine is very effective in treatment-resistant depression, but it is...